References
Uchiyama K, Odahara S, Nakamura M, et al. The fatty acid profile of the erythrocyte membrane in initial-onset inflammatory bowel disease patients. Dig Dis Sci. 2013 (Epub ahead of print). doi:10.1007/s10620-012-2508-6.
Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol. 2010;4:478–482.
Falagas ME, Makris GC, Matthaiou DK, et al. Statins for infection and sepsis: a systematic review of clinical evidence. J Antimicrob Chem. 2008;61:774–785.
McGuire T, Dobesh P, Klepser D, et al. Clinically important interaction between statin drugs and Clostridium difficile toxin? Med Hypotheses. 2009;73:1045–1047.
Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012;36:1032–1039.
Harputluoglu H, Dizdar O, Karaahmet F, et al. Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors. Breast Cancer Res Treat. 2008;110:541.
Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karaahmet, F., Basar, O., Coban, S. et al. Dyslipidemia and Inflammation in Patients with Inflammatory Bowel Disease. Dig Dis Sci 58, 1806–1807 (2013). https://doi.org/10.1007/s10620-013-2614-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-013-2614-0